CME Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
CME Group Inc is not a strong buy for a beginner, long-term investor at this moment. While the company has strong financial performance and positive growth initiatives, the lack of significant trading signals, neutral insider and hedge fund sentiment, recent congressional sales, and mixed analyst ratings suggest that it may be better to wait for a more favorable entry point.
The technical indicators show a generally bullish trend with SMA_5 > SMA_20 > SMA_200 and MACD above 0. However, RSI is neutral at 65.246, and the stock is trading close to its pivot level of 298.055, indicating limited immediate upside potential.
CME has increased its quarterly dividend by 4%, reflecting improved cash flow and profitability.
The company plans to launch single-stock futures this summer, which could enhance market liquidity and provide new investment opportunities.
Strong Q4 financial performance with revenue up 39.14% YoY and net income up 35.23% YoY.
Congress members have sold shares in CME recently, indicating a cautious stance.
Mixed analyst ratings, with some maintaining Neutral or Underweight ratings.
Stock trend analysis suggests a potential decline of -2.24% in the next week and -10.8% in the next month.
CME Group reported strong financials in Q4 2025, with revenue increasing by 39.14% YoY to $3.425 billion, net income up 35.23% YoY to $1.168 billion, and EPS rising by 35% YoY to $3.24. This reflects robust growth and profitability.
Analyst ratings are mixed. UBS raised the price target to $310 with a Neutral rating, Morgan Stanley raised it to $340 with an Overweight rating, and TD Cowen raised it to $328 with a Buy rating. However, JPMorgan and BofA maintain Underweight and Underperform ratings, respectively, citing valuation concerns and mixed outlooks for exchanges.
